Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
Day One Biopharmaceuticals (Nasdaq: DAWN), a company focused on developing targeted therapies for life-threatening diseases, has announced its plans to report third quarter 2024 financial results on Wednesday, October 30, 2024. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and corporate progress.
Interested parties can access the live audio webcast on the Day One Investors & Media page. For those unable to attend the live event, an archived version of the webcast will be available for replay on the Events & Presentations section of the same page for 30 days following the event.
Day One Biopharmaceuticals (Nasdaq: DAWN), un'azienda focalizzata nello sviluppo di terapie mirate per malattie potenzialmente letali, ha annunciato i suoi piani per riportare i risultati finanziari del terzo trimestre 2024 il mercoledì 30 ottobre 2024. L'azienda ospiterà una conferenza telefonica dal vivo e una webcasting alle 4:30 p.m. ET per discutere i risultati finanziari e i progressi aziendali.
Le parti interessate possono accedere alla webcasting audio dal vivo sulla pagina Day One Investors & Media. Per coloro che non possono partecipare all'evento dal vivo, una versione archiviata della webcasting sarà disponibile per il replay nella sezione Eventi e Presentazioni della stessa pagina per 30 giorni dopo l'evento.
Day One Biopharmaceuticals (Nasdaq: DAWN), una empresa centrada en desarrollar terapias dirigidas para enfermedades que amenazan la vida, ha anunciado sus planes de informar sobre los resultados financieros del tercer trimestre de 2024 el miércoles 30 de octubre de 2024. La empresa realizará una llamada de conferencia y una transmisión web en vivo a las 4:30 p.m. ET para discutir los resultados financieros y el progreso corporativo.
Las partes interesadas pueden acceder a la transmisión de audio en vivo en la página de Day One Investors & Media. Para aquellos que no puedan asistir al evento en vivo, una versión archivada de la transmisión estará disponible para su reproducción en la sección de Eventos y Presentaciones de la misma página durante 30 días después del evento.
데이 원 바이오파마슈티컬스 (Nasdaq: DAWN)는 생명을 위협하는 질병을 위한 표적 치료제를 개발하는 회사로, 2024년 3분기 재무 결과를 2024년 10월 30일 수요일에 발표할 계획이라고 발표했습니다. 회사는 오후 4시 30분 ET에 재무 결과 및 기업 진행 상황에 대해 논의하기 위한 라이브 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
관심 있는 분들은 데이 원 투자자 및 미디어 페이지에서 라이브 오디오 웹캐스트에 접근할 수 있습니다. 라이브 이벤트에 참석할 수 없는 분들을 위해 웹캐스트의 아카이브 버전이 이벤트 이후 30일 동안 같은 페이지의 이벤트 및 프레젠테이션 섹션에서 다시 보실 수 있습니다.
Day One Biopharmaceuticals (Nasdaq: DAWN), une société axée sur le développement de thérapies ciblées pour des maladies menaçant la vie, a annoncé son intention de publier ses résultats financiers du troisième trimestre 2024 le mercredi 30 octobre 2024. La société organisera une conférence téléphonique en direct et un webinaire à 16h30 ET pour discuter des résultats financiers et des avancées de l'entreprise.
Les parties intéressées peuvent accéder à la webdiffusion audio en direct sur la page Day One Investors & Media. Pour ceux qui ne peuvent pas assister à l'événement en direct, une version archivée de la webdiffusion sera disponible en replay dans la section Événements et Présentations de la même page pendant 30 jours après l'événement.
Day One Biopharmaceuticals (Nasdaq: DAWN), ein Unternehmen, das sich auf die Entwicklung gezielter Therapien für lebensbedrohliche Krankheiten konzentriert, hat seine Pläne bekannt gegeben, die finanziellen Ergebnisse des dritten Quartals 2024 am Mittwoch, den 30. Oktober 2024 zu berichten. Das Unternehmen wird um 16:30 Uhr ET eine Live-Konferenzschaltung und Webcast veranstalten, um die finanziellen Ergebnisse und den Unternehmensfortschritt zu besprechen.
Interessierte Parteien können den Live-Audio-Webcast auf der Seite Day One Investors & Media abrufen. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine archivierte Version des Webcasts 30 Tage nach der Veranstaltung in der Sektion Veranstaltungen und Präsentationen derselben Seite zur Verfügung stehen.
- None.
- None.
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024.
Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™), DAY301 and a VRK1 inhibitor program.
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When will Day One Biopharmaceuticals (DAWN) report its Q3 2024 financial results?
What time is Day One Biopharmaceuticals' (DAWN) Q3 2024 earnings call?
How can I access Day One Biopharmaceuticals' (DAWN) Q3 2024 earnings webcast?
How long will the replay of Day One Biopharmaceuticals' (DAWN) Q3 2024 earnings call be available?
